Imperial College London

Professor Kausik Ray

Faculty of MedicineSchool of Public Health

Chair in Public Health (Clinical)



+44 (0)20 7594 0716k.ray




Mrs Jennifer Landmann +44 (0)20 7594 9602




320Reynolds BuildingCharing Cross Campus





Professor Ray is currently Professor of Public Heath in the Department of Public Health and Primary Care at Imperial College London , Honorary Consultant Cardiologist at the Imperial College NHS Trust and Director of ICTU-Global which is an academic ARO.

He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, my MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.

His research involves lipids, diabetes and population health serving as global lead for trials and registries. Since 2018 Professor Ray has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine. In 2023 he was inducted as a Fellow of the Academy of Medical Sciences, which is UK’s highest honour for clinician scientists.

His research interests have focused on the prevention of cardiovascular disease with a special interest in lipids and diabetes. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. His work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA.  He continue to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. He has received research grants including from the British Heart Foundation, the Wellcome Trust, Pfizer, Amgen, Sanofi, MSD, and the European Atherosclerosis Society (EAS). Currently he leads the EAS Familial Hypercholesterolaemia (FH) Studies collaboration which is the first global registry for FH and now includes approximately sixty countries, and is in the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London. 

Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap, Chair for Global Council for Heart Health, National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now. He is  a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians. He has been the national lead investigator and have served on the steering and executive committees for several major medical trials. He is currently involved in eight trials including PI of ORION 1 and BETONMACE.

He has published over 200 research articles in numerous journals including the NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal, which have been cited over 150,000 times.



Ray KK, Bloedon L, Li N, et al., 2024, Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Authors' reply., Lancet Diabetes Endocrinol, Vol:12, Pages:228-229

Nicholls SJ, Nelson AJ, Lincoff AM, et al., 2024, Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial., Jama Cardiol, Vol:9, Pages:245-253

Lehrke M, Vogt A, Schettler V, et al., 2024, Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study., Adv Ther, Vol:41, Pages:1184-1200

Ray KK, Gunn LH, Conde LG, et al., 2024, Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention., Atherosclerosis, Vol:391

Holtrop J, Bhatt DL, Ray KK, et al., 2024, Impact of the 2021 ESC Prevention Guideline's stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD., Eur J Prev Cardiol

More Publications